The first generation of blockbuster cancer drugs produced a decade of high returns for the field’s pioneers – Roche, Novartis AG and Celgene Corp.– and ample cash flow to invest in next-generation products. Those days are over. Nearly every major pharma company today aims to lead in oncology. Pipelines are bulging with competing products, and earning superior returns in a crowded market is increasingly difficult.
No question, oncology is one of the industry’s largest and most attractive sectors, with more than $100 billion in sales,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?